December 30, 2021

2022: The Year of Psilocybin | Numinus Wellness $NUMI $NUMIF

Midas Letter
Midas Letter
2022: The Year of Psilocybin | Numinus Wellness $NUMI $NUMIF

Numinus Wellness Inc (TSE: NUMI, OTCMKTS: NUMIF) is a Canadian company that helps cure people’s mental health through psychedelic-assisted therapies. The Numinus Wellness model – including psychedelic production, research and clinical care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse.

Numinus has three business divisions – a Health Canada-licensed lab developing IP while offering analytics services for revenue generation, an R&D division developing psychedelic-assisted therapeutic protocols to embed in mainstream healthcare, and a health practitioner division delivering treatments in Numinus-owned clinics.

“Numinus Health, which is our clinical infrastructure doing traditional mental health services as well as ketamine assisted psychotherapy and now looking to 2022 is really next year being about implementing and integrating MDMA and psilocybin assisted therapy. Which MDMA is expected to be legal for therapy in 2023. So, it’s really getting the foundation in place to be ready for that.” – Numinus Wellness CEO Payton Nyquvest

Numinus was the first Canadian public company to complete a legal harvest of psilocybin (magic mushrooms). But 2022 could be the year that psilocybin finally comes to market. There are numerous section 56 exemptions within the Controlled Drugs and Substances Act that Health Canada has granted for psilocybin use. These exemptions may suggest that broader medical use of psilocybin may be on the horizon. Numinus is looking to take advantage and has psilocybin extract products when they can.

“You’re seeing a really interesting regulatory environment in Canadain in particular at the moment around psilocybin which may allow for us to start to have psilocybin-based products in markets next year as well. You’re seeing a couple of interesting catalysts around the psychotherapy side of things and starting to be able to find a market for the drug itself outside of research.” – Numinus Wellness CEO Payton Nyquvest

Watch the full CEO interview to learn about Numinus’s uplisting to the TSX, future senior US listings, acquisitions like the Neurology Centre of Toronto, and the company using psilocybin to cure mental health problems.


00:00 – Numinus Wellness CEO Payton Nyquvest
00:38 – Numinus developments
01:36 – Pathway to profitability
03:03 – Patient experience
05:12 – Psychedelics as a cure
05:54 – Are psychedelic treatments available to everyone?
09:08 – TSX uplisting

Related Articles


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.